Literature DB >> 21503785

In with the new: the determinants of prescribing innovation by general practitioners in Ireland.

Jane Bourke1, Stephen Roper.   

Abstract

An important element of the process by which new drugs achieve widespread use is their adoption by GPs. In this paper, we explore the factors that shape the timing of the first prescription of six new drugs by General Practitioners in Ireland. Our analysis is based on a dataset that matches prescription data with data on GP characteristics. We then use duration analysis to explore both equilibrium and non-equilibrium determinants of prescribing innovation. Our study highlights a range of commonalities across all of the drugs considered and suggests the importance of GP and practice characteristics in shaping prescribing decisions. We also find strongly significant, and consistently signed, stock and order effects across these drugs: GPs who have a track record of early adoption tend also to be early adopters of other new drugs; and, the larger the proportion of GPs which have already adopted a new drug the slower is subsequent adoption. Epidemic and learning effects are also evident with slower adoption by rural practices and among those GPs with narrower prescribing portfolios.

Mesh:

Substances:

Year:  2011        PMID: 21503785     DOI: 10.1007/s10198-011-0311-5

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  14 in total

1.  Diffusion of new drugs in Danish general practice.

Authors:  F H Steffensen; H T Sørensen; F Olesen
Journal:  Fam Pract       Date:  1999-08       Impact factor: 2.267

2.  Prescribing new drugs: qualitative study of influences on consultants and general practitioners.

Authors:  M I Jones; S M Greenfield; C P Bradley
Journal:  BMJ       Date:  2001-08-18

3.  The adoption of new drugs by doctors practising in group and solo practice.

Authors:  P M Williamson
Journal:  Soc Sci Med       Date:  1975 Apr-May       Impact factor: 4.634

4.  An evaluation of the impact of NICE guidance on GP prescribing.

Authors:  Bernard Wathen; Tara Dean
Journal:  Br J Gen Pract       Date:  2004-02       Impact factor: 5.386

5.  Does the early adopter of drugs exist? A population-based study of general practitioners' prescribing of new drugs.

Authors:  Torben Dybdahl; Morten Andersen; Jens Søndergaard; Jakob Kragstrup; Ivar Sønbø Kristiansen
Journal:  Eur J Clin Pharmacol       Date:  2004-10-21       Impact factor: 2.953

6.  General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study.

Authors:  Torben Dybdahl; Morten Andersen; Jakob Kragstrup; Ivar Sønbø Kristiansen; Jens Søndergaard
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

7.  Competition in general practice: prescriptions to the elderly in a list patient system.

Authors:  Inger Cathrine Kann; Erik Biørn; Hilde Lurås
Journal:  J Health Econ       Date:  2010-07-17       Impact factor: 3.883

8.  Characterizing early prescribers of newly marketed drugs in Canada: a population-based study.

Authors:  Anita Kozyrskyj; Colette Raymond; Amber Racher
Journal:  Eur J Clin Pharmacol       Date:  2007-03-23       Impact factor: 2.953

Review 9.  New medicines in primary care: a review of influences on general practitioner prescribing.

Authors:  A Mason
Journal:  J Clin Pharm Ther       Date:  2008-02       Impact factor: 2.512

10.  Influences on GPs' decision to prescribe new drugs-the importance of who says what.

Authors:  Helen Prosser; Solomon Almond; Tom Walley
Journal:  Fam Pract       Date:  2003-02       Impact factor: 2.267

View more
  8 in total

Review 1.  Prescribing and practice development decision-making in Irish general practices.

Authors:  J Bourke
Journal:  Ir J Med Sci       Date:  2015-06-30       Impact factor: 1.568

2.  What are the current 'top five' perceived educational needs of Irish general practitioners?

Authors:  Stephanie Dowling; Jason Last; Henry Finnegan; Kieran O'Connor; Walter Cullen
Journal:  Ir J Med Sci       Date:  2019-06-12       Impact factor: 1.568

Review 3.  Premium inflation in the Irish private health insurance market: drivers and consequences.

Authors:  B Turner
Journal:  Ir J Med Sci       Date:  2013-03-10       Impact factor: 1.568

4.  Regional Variance of the Early Use of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease.

Authors:  Reiko Inoue; Hiroshi Nishi; Daisuke Inoue; Kenjiro Honda; Masaomi Nangaku
Journal:  Kidney360       Date:  2020-06-16

Review 5.  Factors affecting the uptake of new medicines: a systematic literature review.

Authors:  Ágnes Lublóy
Journal:  BMC Health Serv Res       Date:  2014-10-20       Impact factor: 2.655

6.  Association between physician adoption of a new oral anti-diabetic medication and Medicare and Medicaid drug spending.

Authors:  Ilinca D Metes; Lingshu Xue; Chung-Chou H Chang; Haiden A Huskamp; Walid F Gellad; Wei-Hsuan Lo-Ciganic; Niteesh K Choudhry; Seth Richards-Shubik; Hasan Guclu; Julie M Donohue
Journal:  BMC Health Serv Res       Date:  2019-10-16       Impact factor: 2.655

7.  Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review.

Authors:  Kristina Medlinskiene; Justine Tomlinson; Iuri Marques; Sue Richardson; Katherine Stirling; Duncan Petty
Journal:  BMC Health Serv Res       Date:  2021-11-05       Impact factor: 2.655

8.  Impact of participation in continuing medical education small group learning (CME-SGL) on the stress, morale, and professional isolation of rurally-based GPs: a qualitative study in Ireland.

Authors:  Stephanie Dowling; Jason Last; Henry Finnegan; Pat Daly; John Bourke; Conor Hanrahan; Pat Harrold; Geoff McCombe; Walter Cullen
Journal:  BJGP Open       Date:  2019-10-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.